ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Children With Refractory or Relapsed ALL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00187083
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : June 4, 2008
Sponsor:
Information provided by:
St. Jude Children's Research Hospital

September 12, 2005
September 16, 2005
June 4, 2008
February 1997
December 2003   (Final data collection date for primary outcome measure)
To compare in a randomized trial the depletion of asparagine in patients who receive the native form of asparaginase or PEG-asparaginase during induction therapy. [ Time Frame: December 2003 ]
  • • To give the anticancer drug topotecan to see if the drug has an effect on the leukemia.
  • • To assess the activity of two different forms of the chemotherapy drug Asparaginase, to measure drug levels in the blood, and to look at the side effects.
  • • To find out how many subjects achieve a remission (no evidence of leukemia) with the initial chemotherapy (induction).
  • • To study the levels of certain enzymes in leukemia cells and see if the levels show a relationship to chemotherapy response.
  • • To study the changes in the white blood cells after treatment with etoposide (VP-16).
Complete list of historical versions of study NCT00187083 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of Children With Refractory or Relapsed ALL
A Study of Children With Refractory or Relapsed Acute Lymphoblastic Leukemia (ALLR16)
The main purpose of this study is to find out which form of asparaginase (the native E. coli/Erwinia) or PEG-asparaginase) is more effective during induction treatment for children with acute lymphoblastic leukemia that has come back after treatment (relapsed) or is resistant to treatment (refractory)

The present protocol will compare the biologic effects of PEG-asparaginase vs native-forms of asparaginase in a randomized trial using the same dosages and schedules used in the POG 9411 study. Comprehensive studies, including the measurement of antibodies and asparagine levels as well as the pharmacokinetics of L-asparaginase, will be performed. This protocol will also study the changes in topoisomerase I and topoisomerase II levels and the fractions of topoisomerase I/II translocations in malignant lymphoblasts after upfront window topotecan therapy, and correlate oncolytic response with these changes.

Secondary objectives include:

  • To compare changes in asparagine levels 28 days after initiation of treatment with asparaginase between the two groups.
  • To estimate the pharmacokinetics of L-asparaginase, compare the pharmacokinetics between the two groups of patients, and correlate the pharmacokinetics with the development of antibody to asparaginase and depletion of asparagine.
  • To measure the pharmacokinetics and pharmacodynamics of topotecan in patients with recurrent acute lymphoblastic leukemia
  • To determine whether the frequency of recombinogenesis in lymphocytes is increased during or after etoposide therapy relative to the pre-therapy level, and to explore whether etoposide pharmacokinetics are related to the Day 7 or post-therapy level of recombinogenesis.

Detailed Description of Treatment Plan

WINDOW Topotecan 2.4 mg/m2 ; IV over 30 min in 5 doses Days 1-5

STANDARD INDUCTION Dexamethasone 6 mg/m2/day orally Days 8-35 Vincristine 1.5 mg/m2 (max 2.0 mg) days 8, 15, 22, 29

RANDOMIZE E. coli asparaginase 10,000 U/m2/day IM (or Erwinia if previous allergy to E. coli) Days 8, 11, 13, 15, 18, 20, 22, 25, 27, 29, 32, 34

OR

PEG-Asparaginase 2500 U/m2/day IM Days 8, 15, 22, 29

ITHMA Days 8, 22, 36

CONSOLIDATION

Fludarabine: 15 mg/m2 IV over 30 min; days 1,2,3,4 Ara-C: 2 g/m2 IV days 1,2,3,4

Patients who achieve remission on R16 induction or consolidation may be eligible for either a matched sibling or a fully matched/one-antigen-mismatched unrelated donor transplant

For patients not undergoing bone marrow transplant:

SECONDARY CONSOLIDATION

VP 16: 50 mg/m2 PO qd for 14 days. Vincristine: 1.5 mg/m2 (max 2.0 mg) IV; days 1, 8. IT MHA day 1

CONTINUATION CHEMOTHERAPY

Cycle 1:

Cyclophosphamide 1 g/m2 IV on days 1 and 2 Vincristine 1.5 mg/m2 IV on day 1 (max 2.0 mg)

Cycle 2:

VP-16 50 mg/m2 day PO daily x 14 days Decadron 6 mg/m2 PO daily ) TID x 14 days Vincristine 1.5 mg/m2 IV (max 2 mg) on days 1 and 8.

Cycle 3:

HD MTX 5 gm/m2 continuous infusion over 24 hrs E. coli Asparaginase 10,000 U/m2/dose IM qod x3 or PEG Asparaginase 2500 U/m2/dose IM x 1 (maintain same randomization for Asparaginase preparation as during induction)

Cycle 4:

High Dose Ara-C 2 g/m2/dose IV over 2 hrs q 12 hrs x 3 doses.[Total dose 6 gm/m2] Idarubicin 12 mg/m2 IV over 30 min X 1 [after completion of first dose of Ara-C] IT MHA on day 1 prior to the HDARA-C (dose of ITMHA is age adjusted as outlined in section 7.3)

STANDARD CONTINUATION CHEMOTHERAPY

Patients will receive 4-week rotational cycles of chemotherapy with the following pairs of drugs for total treatment duration of 17 months.

Week #1 Cyclophosphamide (300 mg/m2 IV) + VCR (1.5 mg/m2 IV; max 2 mg). Week #2 VM26 (200 mg/m2 IV) + Ara C (300 mg/m2 IV). Week #3 MTX (MTX should be given IM or as a 2 hr IV infusion if the patient has had previous cranial iradiation) (40 mg/m2 IV/IM) + 6 MP (75 mg/m2 PO q HS x 7) Week #4 MTX (MTX should be given IM or as a 2 hr IV infusion if the patient has had previous cranial irradiation)(40 mg/m2 IV/IM) + 6 MP (75 mg/m2 PO q HS x 7)

IT MHA: Given every 8 weeks throughout standard continuation chemotherapy for patients with CNS 1 status Given every 4 weeks for patients with CNS 2/3 status who will receive CSI at the end of chemotherapy

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Acute Lymphoblastic Leukemia
  • Drug: Topotecan, dexamethasone, vincristine
    See Detailed Description section for details of treatment interventions.
  • Drug: E. coli Asparaginase, PEG-L-asparaginase
    See Detailed Description section for details of treatment interventions.
  • Drug: erwinia asparaginase
    See Detailed Description section for details of treatment interventions.
  • Drug: fludarabine, methotrexate, mercaptopurine
    See Detailed Description section for details of treatment interventions.
  • Drug: idarubicin, etoposide, cytarbine, teniposide
    See Detailed Description section for details of treatment interventions.
  • Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
    See Detailed Description section for details of treatment interventions.
  • Experimental: 1
    Native asparaginase
    Interventions:
    • Drug: Topotecan, dexamethasone, vincristine
    • Drug: E. coli Asparaginase, PEG-L-asparaginase
    • Drug: erwinia asparaginase
    • Drug: fludarabine, methotrexate, mercaptopurine
    • Drug: idarubicin, etoposide, cytarbine, teniposide
    • Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
  • Experimental: 2
    PEG-asparaginase
    Interventions:
    • Drug: Topotecan, dexamethasone, vincristine
    • Drug: E. coli Asparaginase, PEG-L-asparaginase
    • Drug: erwinia asparaginase
    • Drug: fludarabine, methotrexate, mercaptopurine
    • Drug: idarubicin, etoposide, cytarbine, teniposide
    • Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
88
December 2003
December 2003   (Final data collection date for primary outcome measure)

Inclusion Criteria

For patients treated on frontline protocols at St. Jude:

  • ALL in isolated bone marrow relapse, or combined marrow and extramedullary relapse, during or after treatment with multi-agent chemotherapy (TOTAL XI, XII, XIIIA, XIIIB), or isolated extramedullary relapse after treatment on TOTXII.
  • Patients with recurrent T-Cell non-Hodgkin's lymphoma who relapse in the bone marrow with >25% blasts

For patients not treated on front-line St. Jude protocols:

• ALL in isolated bone marrow relapse, or isolated extramedullary relapse, or combined marrow and extramedullary relapse.

All patients:

  • First relapse after receiving primary therapy or during primary therapy
  • Life expectance of at least 8 weeks
  • ECOG score 0-2 Exclusion criteria
  • Life expectancy < 8 weeks
Sexes Eligible for Study: All
up to 18 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00187083
ALLR16
No
Not Provided
Not Provided
Name/Official Title: Sima Jeha, MD / Principal Investigator, St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Not Provided
Principal Investigator: Sima Jeha, MD St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
June 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP